Global Post Menopausal Vaginal Atrophy Drugs Market 2016-2020 report is the latest addition to Sandlerresearch.org industry research reports collection, Non-estrogenic therapies in PVA treatment are a paradigm shift from systemic estrogen therapies such as creams, patches, and gels. In addition, the launch of late-stage pipeline products is expected to shift the attention from vaginal creams and OTC classes toward vaginal tablets and oral therapies. For instance, the recent launch of two non-estrogenic therapies with improved safety profiles, Osphena by Shionogi and BZA/CE by Bayer, will allow manufacturers to tap a large pool of untreated people.
The analysts forecast global PVA drugs market to grow at a CAGR of 7.13% during the period 2016-2020.
The report, Global Post-Menopausal Vaginal Atrophy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Inquire for more details @ http://www.sandlerresearch.org/inquire-before-buying?rname=53636 .
Main players in the Global Post-Menopausal Vaginal Atrophy Drugs Market: Pfizer Inc., Allergan Inc., Shionogi & Co. Ltd., Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd. Other Prominent Vendors in the market are: Bayer, Bionovo, EndoCeutics, Foamix Pharmaceuticals, Ligand Pharmaceuticals, Pantarhei Bioscience, Pep-Tonic Medical, TherapeuticsMD, and Upsher-Smith Laboratories.
Further, the report states that the market is currently served by generic products due to the patent expiries of branded products such as Premarin, which lost its patent in 2012. The patent of Colpotrophine also expired in 2015. Patent expiries will lead to the entry of generic versions of the particular drugs in the market, resulting in the sales erosion of branded products. This will result in heavy financial loss to the parent drug makers.
Purchase a copy of Global Post-Menopausal Vaginal Atrophy Drugs Market 2016-2020 report @ http://www.sandlerresearch.org/purchase?rname=53636 for US $2500.
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for PVA drugs
Exhibit 03: Symptoms of PVA
Exhibit 05: Percentage of major vaginal atrophy symptoms in postmenopausal women
Exhibit 06: Causes of PVA
Exhibit 07: Effects of estrogen deficiency
Exhibit 08: Treatment for PVA
Exhibit 09: Some hormonal treatments for PVA
Exhibit 10: Top concerns associated with OTC lubricants or moisturizers for PVA
Exhibit 11: Top concerns about use of vaginal estrogen for PVA
Exhibit 12: Prevalence of vaginal atrophy symptoms in postmenopausal women by country 2014 and more..
Inquire for Discount @ http://www.sandlerresearch.org/discount?rname=53636
Sandlerresearch.org is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.